Molecular biology and phase 1 study of GM-CSF and intrathecal trastuzumab in children with recurrent -posterior fossa ependymoma.

Saved in:
Bibliographic Details
Title: Molecular biology and phase 1 study of GM-CSF and intrathecal trastuzumab in children with recurrent -posterior fossa ependymoma.
Authors: Griesinger AM; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA.; Clinical Science Graduate Program, Anschutz Medical Campus, Aurora, Colorado, USA., Widener M; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA., Donson AM; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA., Mettetal A; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA., Hankinson TC; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA.; Department of Neurosurgery, Anschutz Medical Campus, Aurora, Colorado, USA., Handler M; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Neurosurgery, Anschutz Medical Campus, Aurora, Colorado, USA., Mulcahy Levy JM; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA.; Clinical Science Graduate Program, Anschutz Medical Campus, Aurora, Colorado, USA., Lindsay HB; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA., Macy ME; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA., Foreman NK; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA.; Clinical Science Graduate Program, Anschutz Medical Campus, Aurora, Colorado, USA., Dorris K; Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, Colorado, USA.; Department of Pediatrics, University of Colorado Denver, Aurora, Colorado, USA.; Cogent Biosciences, Pearl Street Innovation Campus, Boulder, Colorado, USA.
Source: Neuro-oncology [Neuro Oncol] 2026 Jul 01; Vol. 28 (7), pp. 1783-1793.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1523-5866
DOI:10.1093/neuonc/noag066